Your browser doesn't support javascript.
loading
FAM3D: A gut secreted protein and its potential in the regulation of glucose metabolism.
Moser, Caroline; Gosselé, Katherine A; Balaz, Miroslav; Balazova, Lucia; Horvath, Carla; Künzle, Patricia; Okreglicka, Katarzyna Maria; Li, Fengqi; Blüher, Matthias; Stierstorfer, Birgit; Hess, Eva; Lamla, Thorsten; Hamilton, Bradford; Klein, Holger; Neubauer, Heike; Wolfrum, Christian; Wolfrum, Susanne.
Afiliação
  • Moser C; Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology (ETH) Zurich, 8603 Schwerzenbach, Switzerland.
  • Gosselé KA; Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology (ETH) Zurich, 8603 Schwerzenbach, Switzerland.
  • Balaz M; Biomedical Research Center, Institute of Experimental Endocrinology; SLOVAK ACADEMY OF SCIENCES (SAS), Bratislava, Slovac Republic.
  • Balazova L; Biomedical Research Center, Institute of Experimental Endocrinology; SLOVAK ACADEMY OF SCIENCES (SAS), Bratislava, Slovac Republic.
  • Horvath C; Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology (ETH) Zurich, 8603 Schwerzenbach, Switzerland.
  • Künzle P; Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology (ETH) Zurich, 8603 Schwerzenbach, Switzerland.
  • Okreglicka KM; Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland.
  • Li F; Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland.
  • Blüher M; Medical Department III (Endocrinology, Nephrology and Rheumatology), University of Leipzig, Leipzig, Germany; Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
  • Stierstorfer B; Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Hess E; Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Lamla T; Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Hamilton B; Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Klein H; Global Computational Biology and Digital Sciences Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Neubauer H; Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany.
  • Wolfrum C; Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology (ETH) Zurich, 8603 Schwerzenbach, Switzerland. Electronic address: christian.wolfrum@ethz.ch.
  • Wolfrum S; Laboratory of Organic Chemistry, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland. Electronic address: wolfrum@org.chem.ethz.ch.
Peptides ; 167: 171047, 2023 09.
Article em En | MEDLINE | ID: mdl-37328068
ABSTRACT
The number of diabetic patients is rising globally and concomitantly so do the diabetes associated complications. The gut secretes a variety of proteins to control blood glucose levels and/or food intake. As the drug class of GLP-1 agonists is based on a gut secreted peptide and the positive metabolic effects of bariatric surgery are at least partially mediated by gut peptides, we were interested in other gut secreted proteins which have yet to be explored. In this respect we identified the gut secreted protein FAM3D by analyzing sequencing data from L- and epithelial cells of VSG and sham operated as well as chow and HFD fed mice. FAM3D was overexpressed in diet induced obese mice via an adeno-associated virus (AAV), which resulted in a significant improvement of fasting blood glucose levels, glucose tolerance and insulin sensitivity. The liver lipid deposition was reduced, and the steatosis morphology was improved. Hyperinsulinemic clamps indicated that FAM3D is a global insulin sensitizer and increases glucose uptake into various tissues. In conclusion, the current study demonstrated that FAM3D controls blood glucose levels by acting as an insulin sensitizing protein and improves hepatic lipid deposition.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Fígado Gorduroso Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Fígado Gorduroso Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article